T-cell replete cord vs comparator cohort EFS. (A) In patients who were flow MRD positive going into transplant, T-replete CB recipients had significantly better EFS compared with recipients of other transplants, 2-year EFS 50% (95% CI, 34-64) vs 21% (95% CI, 12-32) (HR, 0.55 [95% CI, 0.34-0.90]; P = .017). (B) For patients who were MRD negative at transplant, there was no significant difference in EFS between patients in the T-replete cord vs comparator group, 2-year EFS was 79% (95% CI, 64-88) for T-replete cord recipients and 71% (95% CI, 64-78) for the comparator group (HR, 0.86 [95% CI, 0.45-1.65]; P = .649).